Acerus Drug Patent Portfolio
Acerus owns 2 orange book drugs protected by 11 US patents Given below is the list of Acerus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | 17 Mar, 2034 | Active |
| US11419914 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US12090190 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US9539302 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin | 26 Sep, 2024 | Expired |
| US8574622 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
| US8784869 | Controlled release delivery system for nasal applications and methods of treatment | 04 Feb, 2024 | Expired |
| US8784882 | Controlled release delivery system for nasal applications and method of treatment | 04 Feb, 2024 | Expired |
| US8877230 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
Latest Legal Activities on Acerus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acerus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2024 | US9539302 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2024 | US11090312 |
|
Email Notification
Critical
| 02 Jul, 2024 | US11090312 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Aug, 2022 | US11419914 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Aug, 2022 | US11419914 |
|
Email Notification
Critical
| 04 Aug, 2022 | US11419914 |
|
Issue Notification Mailed
Critical
| 03 Aug, 2022 | US11419914 |
|
Email Notification
Critical
| 15 Jul, 2022 | US11419914 |
| Mailing Corrected Notice of Allowability | 15 Jul, 2022 | US11419914 |
| Corrected Notice of Allowability | 12 Jul, 2022 | US11419914 |
|
Pubs Case Remand to TC
Critical
| 11 Jul, 2022 | US11419914 |
| Dispatch to FDC | 06 Jul, 2022 | US11419914 |
|
Email Notification
Critical
| 05 Jul, 2022 | US11419914 |
| Mailing Corrected Notice of Allowability | 05 Jul, 2022 | US11419914 |
|
Mail Notice of Allowance
Critical
| 30 Jun, 2022 | US11419914 |
Acerus Drug Patents' Oppositions Filed in EPO
Acerus drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 12, 2018, by Ferring B.V.. This opposition was filed on patent number EP10790053A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17168865A | Aug, 2020 | Ferring B.V. | Revoked |
| EP09796558A | May, 2019 | Ferring B.V. | Patent maintained as amended |
| EP10790053A | Mar, 2018 | Ferring B.V. | Granted and Under Opposition |
Acerus's Family Patents
Acerus Drug List
Given below is the complete list of Acerus's drugs and the patents protecting them.
1. Natesto
Natesto is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
17 Mar, 2034
(8 years from now)
| Active |
| US8574622 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(1 year, 11 months ago)
| Expired |
| US8784869 | Controlled release delivery system for nasal applications and methods of treatment |
04 Feb, 2024
(1 year, 11 months ago)
| Expired |
| US8784882 | Controlled release delivery system for nasal applications and method of treatment |
04 Feb, 2024
(1 year, 11 months ago)
| Expired |
| US8877230 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Natesto's drug page
2. Noctiva
Noctiva is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419914 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US12090190 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US9539302 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin |
26 Sep, 2024
(1 year, 3 months ago)
| Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(2 years ago)
| Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noctiva's drug page